Gossamer Bio, Inc. (GOSS)
8.89
-0.02
(-0.17%)
USD |
NASDAQ |
Oct 15, 16:00
9.05
+0.16
(+1.80%)
After-Hours: 05:52
Gossamer Bio Research and Development Expense (Quarterly) : 26.41M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 26.41M |
| March 31, 2026 | 43.07M |
| December 31, 2025 | 48.93M |
| September 30, 2025 | 45.54M |
| June 30, 2025 | 41.57M |
| March 31, 2025 | 38.04M |
| December 31, 2024 | 36.00M |
| September 30, 2024 | 34.70M |
| June 30, 2024 | 34.84M |
| March 31, 2024 | 32.13M |
| December 31, 2023 | 29.68M |
| September 30, 2023 | 30.80M |
| June 30, 2023 | 35.85M |
| March 31, 2023 | 37.33M |
| December 31, 2022 | 41.05M |
| September 30, 2022 | 44.05M |
| June 30, 2022 | 41.94M |
| March 31, 2022 | 41.68M |
| Date | Value |
|---|---|
| December 31, 2021 | 40.10M |
| September 30, 2021 | 42.33M |
| June 30, 2021 | 43.45M |
| March 31, 2021 | 40.97M |
| December 31, 2020 | 37.70M |
| September 30, 2020 | 40.67M |
| June 30, 2020 | 37.70M |
| March 31, 2020 | 40.52M |
| December 31, 2019 | 40.13M |
| September 30, 2019 | 39.90M |
| June 30, 2019 | 35.47M |
| March 31, 2019 | 24.81M |
| December 31, 2018 | 25.87M |
| September 30, 2018 | 18.86M |
| June 30, 2018 | 7.898M |
| March 31, 2018 | 2.618M |
| December 31, 2017 | 0.675M |
| September 30, 2017 | 0.212M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp. | 146.30M |
| Arbutus Biopharma Corp. | 2.898M |
| Kura Oncology, Inc. | 61.89M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |